{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33412"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33412","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Strategies for Enhancing the Function of Natural Killer Cells In Vivo Against Hard-To-Treat Solid Tumors","abstract":"Natural killer (NK) cells are a promising approach for cancer immunotherapy. Current evidence from the clinic suggests that NK cells are a safe form of immunotherapy and have demonstrated the ability to improve patient prognosis in hematological malignancies. However, NK cells and immunotherapy overall have delivered modest results against solid tumors. The dampening of NK cell function against solid tumors has been attributed to the immunosuppressive and metabolically hostile tumor microenvironment. To address these limitations, NK cells have been co-cultured with feeder cells expressing membrane-bound IL-21 (mbIL-21). NK cells cultured using this method demonstrate greater proliferation, telomere lengthening, and metabolic reprogramming. However, ex vivo culturing methods have not been rigorously tested in the clinic. Further, evidence from preclinical models suggests that ex vivo-expanded NK cells may not persist long enough to achieve tumor clearance. This has led us to investigate an in vivo-directed approach in which NK cells can be expanded within the body. Further, such an approach could be combined with an ex vivo approach to enhance anti-tumor responses. Here, we utilized multiple approaches, including DNA aptamers, peptides, protein engineering, and protein design, to assess whether NK cell function can be enhanced. Through our protein engineering and protein design approaches, we also demonstrated enhanced tumor control and NK cell proliferation. Our results provide a proof of concept for enhancing NK cell function through different approaches, with varying degrees of success. Taken together, these findings highlight how NK cell therapy can also benefit from in vivo directed approaches.","abstract_html":"Natural killer (NK) cells are a promising approach for cancer immunotherapy. Current evidence from the clinic suggests that NK cells are a safe form of immunotherapy and have demonstrated the ability to improve patient prognosis in hematological malignancies. However, NK cells and immunotherapy overall have delivered modest results against solid tumors. The dampening of NK cell function against solid tumors has been attributed to the immunosuppressive and metabolically hostile tumor microenvironment. To address these limitations, NK cells have been co-cultured with feeder cells expressing membrane-bound IL-21 (mbIL-21). NK cells cultured using this method demonstrate greater proliferation, telomere lengthening, and metabolic reprogramming. However, ex vivo culturing methods have not been rigorously tested in the clinic. Further, evidence from preclinical models suggests that ex vivo-expanded NK cells may not persist long enough to achieve tumor clearance. This has led us to investigate an in vivo-directed approach in which NK cells can be expanded within the body. Further, such an approach could be combined with an ex vivo approach to enhance anti-tumor responses. Here, we utilized multiple approaches, including DNA aptamers, peptides, protein engineering, and protein design, to assess whether NK cell function can be enhanced. Through our protein engineering and protein design approaches, we also demonstrated enhanced tumor control and NK cell proliferation. Our results provide a proof of concept for enhancing NK cell function through different approaches, with varying degrees of success. Taken together, these findings highlight how NK cell therapy can also benefit from in vivo directed approaches.","abstract_has_math":false,"creators":["Moinuddin, Adnan"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences (Molecular Virology and Immunology Program)","school":null,"contributors":[],"advisors":["Ashkar, Ali"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:33:14Z","subjects":["NK cells","cancer immunotherapy","solid tumors"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/1077"],"render_values":[{"text":"https://doi.org/10.71548/1077","href":"https://doi.org/10.71548/1077","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33412","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33412","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33412","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Ashkar, Ali"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences (Molecular Virology and Immunology Program)"]},{"key":"dc:creator","label":"Author","values":["Moinuddin, Adnan"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-07-23T17:11:16Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["NK cells","cancer immunotherapy","solid tumors"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33412","https://doi.org/10.71548/1077"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Natural killer (NK) cells are a promising approach for cancer immunotherapy. Current evidence from the clinic suggests that NK cells are a safe form of immunotherapy and have demonstrated the ability to improve patient prognosis in hematological malignancies. However, NK cells and immunotherapy overall have delivered modest results against solid tumors. The dampening of NK cell function against solid tumors has been attributed to the immunosuppressive and metabolically hostile tumor microenvironment. To address these limitations, NK cells have been co-cultured with feeder cells expressing membrane-bound IL-21 (mbIL-21). NK cells cultured using this method demonstrate greater proliferation, telomere lengthening, and metabolic reprogramming. However, ex vivo culturing methods have not been rigorously tested in the clinic. Further, evidence from preclinical models suggests that ex vivo-expanded NK cells may not persist long enough to achieve tumor clearance. This has led us to investigate an in vivo-directed approach in which NK cells can be expanded within the body. Further, such an approach could be combined with an ex vivo approach to enhance anti-tumor responses. Here, we utilized multiple approaches, including DNA aptamers, peptides, protein engineering, and protein design, to assess whether NK cell function can be enhanced. Through our protein engineering and protein design approaches, we also demonstrated enhanced tumor control and NK cell proliferation. Our results provide a proof of concept for enhancing NK cell function through different approaches, with varying degrees of success. Taken together, these findings highlight how NK cell therapy can also benefit from in vivo directed approaches."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science (MSc)"]},{"key":"dc:title","label":"Title","values":["Strategies for Enhancing the Function of Natural Killer Cells In Vivo Against Hard-To-Treat Solid Tumors"]},{"key":"others:access_status","label":"Others Access Status","values":["embargo"]}]}],"canonical_facts":{"dc:contributor.advisor":["Ashkar, Ali"],"dc:contributor.department":["Medical Sciences (Molecular Virology and Immunology Program)"],"dc:creator":["Moinuddin, Adnan"],"dc:date.accessioned":["2026-07-23T17:11:16Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Natural killer (NK) cells are a promising approach for cancer immunotherapy. Current evidence from the clinic suggests that NK cells are a safe form of immunotherapy and have demonstrated the ability to improve patient prognosis in hematological malignancies. However, NK cells and immunotherapy overall have delivered modest results against solid tumors. The dampening of NK cell function against solid tumors has been attributed to the immunosuppressive and metabolically hostile tumor microenvironment. To address these limitations, NK cells have been co-cultured with feeder cells expressing membrane-bound IL-21 (mbIL-21). NK cells cultured using this method demonstrate greater proliferation, telomere lengthening, and metabolic reprogramming. However, ex vivo culturing methods have not been rigorously tested in the clinic. Further, evidence from preclinical models suggests that ex vivo-expanded NK cells may not persist long enough to achieve tumor clearance. This has led us to investigate an in vivo-directed approach in which NK cells can be expanded within the body. Further, such an approach could be combined with an ex vivo approach to enhance anti-tumor responses. Here, we utilized multiple approaches, including DNA aptamers, peptides, protein engineering, and protein design, to assess whether NK cell function can be enhanced. Through our protein engineering and protein design approaches, we also demonstrated enhanced tumor control and NK cell proliferation. Our results provide a proof of concept for enhancing NK cell function through different approaches, with varying degrees of success. Taken together, these findings highlight how NK cell therapy can also benefit from in vivo directed approaches."],"dc:description.degree":["Master of Science (MSc)"],"dc:identifier.uri":["https://hdl.handle.net/11375/33412","https://doi.org/10.71548/1077"],"dc:subject":["NK cells","cancer immunotherapy","solid tumors"],"dc:title":["Strategies for Enhancing the Function of Natural Killer Cells In Vivo Against Hard-To-Treat Solid Tumors"],"dc:type":["Thesis"],"others:access_status":["embargo"]},"updated_at":"2026-11-18T19:33:14Z"}